KASTELEIN JOHANNES JACOB PIETER

PrivateCIK: 2000389
Location

NAARDEN, P7

KASTELEIN JOHANNES JACOB PIETER (Chief Scientific Officer) sold 81.2% of their position (300K shares) of NEWAMSTERDAM PHARMA CO N.V. on the open market

Open‑market sale worth $9.09M — a major position exit. Review remaining holdings and any 10b5‑1 plan disclosures.

S · 3 sales
DirectorOfficer· Chief Scientific Officer
Since Mar 2026
-300K
Net shares
Net seller
$9.09M
Total sold
3
Open market trades
0B · 3S
9
Total transactions
300K acquired · 600K disposed
Non-Derivative Transactions6

Ordinary Shares

Indirect
M · Option Exercise

Shares

+104.47K

Price / share

Trade value

% of position

150.7%
3/5/2026
69.30K173.77K

Ordinary Shares

Indirect
S · Sale

Shares

104.47K

Price / share

$30.30

Trade value

$3.17M

% of position

60.1%
3/5/2026
173.77K69.30K

Ordinary Shares

Indirect
M · Option Exercise

Shares

+94.12K

Price / share

Trade value

% of position

135.8%
3/6/2026
69.30K163.43K

Ordinary Shares

Indirect
S · Sale

Shares

94.12K

Price / share

$30.32

Trade value

$2.85M

% of position

57.6%
3/6/2026
163.43K69.30K

Ordinary Shares

Indirect
M · Option Exercise

Shares

+101.41K

Price / share

Trade value

% of position

146.3%
3/9/2026
69.30K170.71K

Ordinary Shares

Indirect
S · Sale

Shares

101.41K

Price / share

$30.29

Trade value

$3.07M

% of position

59.4%
3/9/2026
170.71K69.30K
Total

Net shares

+0.00

Net value

-$9.09M

Derivative Transactions3

Option (right to buy)

Indirect
M · Option Exercise
Converts to

Ordinary Shares

104.47K shares

Shares

104.47K

Strike price

Held after

715.76K

Exercisable

3/5/2026

Option (right to buy)

Indirect
M · Option Exercise
Converts to

Ordinary Shares

94.12K shares

Shares

94.12K

Strike price

Held after

621.64K

Exercisable

3/6/2026

Option (right to buy)

Indirect
M · Option Exercise
Converts to

Ordinary Shares

101.41K shares

Shares

101.41K

Strike price

Held after

520.23K

Exercisable

3/9/2026
KASTELEIN JOHANNES JACOB PIETER — Insider Transaction (Form 4) Filed Mar 9, 2026 | Finecho